BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to Buy at ValuEngine

BioCryst Pharmaceuticals (NASDAQ:BCRX) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, ValuEngine reports.

BCRX has been the topic of a number of other research reports. BidaskClub cut shares of BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, October 4th. HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a report on Thursday, October 31st. Bank of America upgraded BioCryst Pharmaceuticals from a “neutral” rating to a “buy” rating and dropped their price target for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. Needham & Company LLC reissued a “hold” rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, November 6th. Finally, Zacks Investment Research downgraded BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 8th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $8.94.

BioCryst Pharmaceuticals stock opened at $2.76 on Tuesday. BioCryst Pharmaceuticals has a 1 year low of $1.38 and a 1 year high of $9.95. The firm’s 50-day moving average is $2.25 and its 200-day moving average is $3.07. The company has a debt-to-equity ratio of 2.38, a quick ratio of 0.94 and a current ratio of 0.96. The company has a market cap of $422.85 million, a P/E ratio of -2.82 and a beta of 2.02.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). The business had revenue of $1.78 million for the quarter, compared to the consensus estimate of $4.54 million. BioCryst Pharmaceuticals had a negative net margin of 1,129.38% and a negative return on equity of 2,511.40%. As a group, sell-side analysts predict that BioCryst Pharmaceuticals will post -1.21 earnings per share for the current year.

In other news, insider Megan Sniecinski bought 45,000 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was purchased at an average price of $1.45 per share, for a total transaction of $65,250.00. Following the transaction, the insider now owns 45,000 shares in the company, valued at $65,250. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jon P. Stonehouse bought 50,000 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was purchased at an average price of $1.45 per share, with a total value of $72,500.00. Following the transaction, the chief executive officer now owns 778,086 shares in the company, valued at approximately $1,128,224.70. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 120,000 shares of company stock worth $174,000. Corporate insiders own 5.20% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its position in shares of BioCryst Pharmaceuticals by 2.6% during the second quarter. BlackRock Inc. now owns 8,925,891 shares of the biotechnology company’s stock worth $33,831,000 after buying an additional 228,525 shares during the period. Vanguard Group Inc. increased its position in BioCryst Pharmaceuticals by 10.7% in the 2nd quarter. Vanguard Group Inc. now owns 6,692,444 shares of the biotechnology company’s stock valued at $25,365,000 after acquiring an additional 648,937 shares during the period. FMR LLC increased its position in BioCryst Pharmaceuticals by 15.9% in the 1st quarter. FMR LLC now owns 3,467,998 shares of the biotechnology company’s stock valued at $28,229,000 after acquiring an additional 475,989 shares during the period. Point72 Asset Management L.P. acquired a new stake in BioCryst Pharmaceuticals in the 3rd quarter valued at approximately $9,340,000. Finally, UBS Group AG raised its stake in BioCryst Pharmaceuticals by 331.0% during the 2nd quarter. UBS Group AG now owns 2,202,794 shares of the biotechnology company’s stock valued at $8,349,000 after acquiring an additional 1,691,681 shares in the last quarter. 89.40% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Read More: Stocks Increasing Dividends

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.